Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-05-2020 | Lymphoma | Original Article

Correlation between combining ¹⁸F–FDG PET/CT metabolic parameters and other clinical features and ALK or ROS1 fusion in patients with non-small-cell lung cancer

Authors: Maomei Ruan, Liu Liu, Lihua Wang, Bei Lei, Xiaoyan Sun, Cheng Chang, Yan Shen, Wenhui Xie

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2020

Abstract

Purpose

Our study intended to explore the association between combining ¹⁸F–FDG PET/CT metabolic parameters and other clinical features and anaplastic lymphoma kinase (ALK) or c-ros oncogene 1 (ROS1) fusion in non-small-cell lung cancer (NSCLC).

Methods

Eight hundred and six patients with wild-type epidermal growth factor receptor (EGFR) mutation were screened for ALK or ROS1 fusion and subjected to ¹⁸F–FDG PET/CT prior to treatment at our hospital. The associations between ALK or ROS1 fusion and clinical characteristics and the PET/CT parameters were analyzed. Multivariate logistic regression analysis was performed to explore independent deterministic factors associated with ALK and ROS1 fusion.

Results

Eighty-two patients (11.7%) with ALK fusion were found. Multivariate analysis demonstrated that high pSUVmax ≥ 10.6, low primary tumor lesion glycolysis (pTLG) < 101.8, young age, nonsmoker status, and high carcinoembryonic antigen (CEA) level correlated with ALK fusion in NSCLC. The receiver operating characteristic (ROC) curve yielded the area under curve (AUC) values of 0.603 and 0.873 for high pSUVmax alone and the combination of the five factors, respectively. Twenty-six patients (5.6%) with ROS1 fusion were found. Multivariate analysis revealed that high pSUVmax ≥ 8.8, young age, and nonsmoker status correlated with ROS1 fusion in NSCLC. The ROC curve yielded AUC values of 0.662 and 0.813 for high pSUVmax alone and the combination of the three factors, respectively.

Conclusion

The study indicated that combining ¹⁸F–FDG PET/CT metabolic parameters and other clinical parameters were correlated with ALK and ROS1 mutation in NSCLC patients and may help to refine the process of optimal patient selection to gene test for targeted therapy.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. https://doi.org/10.3322/caac.21262.CrossRef

Herbst RS, Lippman SM. Molecular signatures of lung cancer--toward personalized therapy. N Engl J Med. 2007;356:76–8. https://doi.org/10.1056/NEJMe068218.CrossRefPubMed

Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist. 2012;17:1351–75. https://doi.org/10.1634/theoncologist.2012-0311.CrossRefPubMedPubMedCentral

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–6. https://doi.org/10.1038/nature05945.CrossRefPubMed

Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–703. https://doi.org/10.1056/NEJMoa1006448.CrossRefPubMedPubMedCentral

Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011;6:942–6. https://doi.org/10.1097/JTO.0b013e31821528d3.CrossRefPubMed

Leighl NB, Rekhtman N, Biermann WA, Huang J, Mino-Kenudson M, Ramalingam SS, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/international association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol. 2014;32:3673–9. https://doi.org/10.1200/jco.2014.57.3055.CrossRefPubMedPubMedCentral

Chin LP, Soo RA, Soong R, Ou SH. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol. 2012;7:1625–30. https://doi.org/10.1097/JTO.0b013e31826baf83.CrossRefPubMed

Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863–70. https://doi.org/10.1200/jco.2011.35.6345.CrossRefPubMedPubMedCentral

10.

Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res. 2015;4:156–64. https://doi.org/10.3978/j.issn.2218-6751.2014.11.11.CrossRefPubMedPubMedCentral

11.

Mazieres J, Zalcman G, Crino L, Biondani P, Barlesi F, Filleron T, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015;33:992–9. https://doi.org/10.1200/jco.2014.58.3302.CrossRefPubMed

12.

Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963–71. https://doi.org/10.1056/NEJMoa1406766.CrossRefPubMedPubMedCentral

13.

Putora PM, Szentesi K, Glatzer M, Rodriguez R, Muller J, Baty F, et al. SUVmax and tumour location in PET-CT predict oncogene status in lung Cancer. Oncol Res Treat. 2016;39:681–6. https://doi.org/10.1159/000450622.CrossRefPubMed

14.

Jadvar H, Alavi A, Gambhir SS. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med. 2009;50:1820–7. https://doi.org/10.2967/jnumed.108.054098.CrossRefPubMedPubMedCentral

15.

Na II, Byun BH, Kim KM, Cheon GJ, Choe du H, Koh JS, et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer (Amsterdam, Netherlands). 2010;67:76–80. https://doi.org/10.1016/j.lungcan.2009.03.010.CrossRef

16.

Mak RH, Digumarthy SR, Muzikansky A, Engelman JA, Shepard JA, Choi NC, et al. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist. 2011;16:319–26. https://doi.org/10.1634/theoncologist.2010-0300.CrossRefPubMedPubMedCentral

17.

Jeong CJ, Lee HY, Han J, Jeong JY, Lee KS, Choi YL, et al. Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma. Clin Nucl Med. 2015;40:e34–9. https://doi.org/10.1097/rlu.0000000000000581.CrossRefPubMed

18.

Lv Z, Fan J, Xu J, Wu F, Huang Q, Guo M, et al. Value of (18)F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients. Eur J Nucl Med Mol Imaging. 2018;45:735–50. https://doi.org/10.1007/s00259-017-3885-z.CrossRefPubMed

19.

Choi H, Paeng JC, Kim DW, Lee JK, Park CM, Kang KW, et al. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. Lung Cancer (Amsterdam, Netherlands). 2013;79:242–7. https://doi.org/10.1016/j.lungcan.2012.11.021.CrossRef

20.

Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in Total lesion glycolysis. Clin Positron Imaging. 1999;2:159–71.CrossRef

21.

Zhang C, Liao C, Penney BC, Appelbaum DE, Simon CA, Pu Y. Relationship between overall survival of patients with non-small cell lung cancer and whole-body metabolic tumor burden seen on postsurgical fluorodeoxyglucose PET images. Radiology. 2015;275:862–9. https://doi.org/10.1148/radiol.14141398.CrossRefPubMedPubMedCentral

22.

Lee EY, Khong PL, Lee VH, Qian W, Yu X, Wong MP. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation. Clin Nucl Med. 2015;40:e190–5. https://doi.org/10.1097/rlu.0000000000000684.CrossRefPubMed

23.

Meng X, Sun X, Mu D, Xing L, Ma L, Zhang B, et al. Noninvasive evaluation of microscopic tumor extensions using standardized uptake value and metabolic tumor volume in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;82:960–6. https://doi.org/10.1016/j.ijrobp.2010.10.064.CrossRefPubMed

24.

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122s–50s. https://doi.org/10.2967/jnumed.108.057307.CrossRefPubMedPubMedCentral

25.

Kahraman D, Holstein A, Scheffler M, Zander T, Nogova L, Lammertsma AA, et al. Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib. Clin Nucl Med. 2012;37:1058–64. https://doi.org/10.1097/RLU.0b013e3182639747.CrossRefPubMed

26.

Stoecklein NH, Klein CA. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer. 2010;126:589–98. https://doi.org/10.1002/ijc.24916.CrossRefPubMed

27.

Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009;9:302–12. https://doi.org/10.1038/nrc2627.CrossRefPubMed

28.

Kosaka N, Tsuchida T, Tsuji K, Shimizu K, Kimura H. Standardized uptake value differences between primary and metastatic lesions in (1)(8)F-FDG PET/CT of patients with lung cancer. Acta Radiol. 2015;56:1329–35. https://doi.org/10.1177/0284185114556705.CrossRefPubMed

29.

Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6:3837–44.PubMed

30.

Wang YW, Tu PH, Lin KT, Lin SC, Ko JY, Jou YS. Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer. Neoplasia (New York, NY). 2011;13:704–15.CrossRef

31.

Yip SS, Kim J, Coroller TP, Parmar C, Velazquez ER, Huynh E, et al. Associations between somatic mutations and metabolic imaging phenotypes in non-small cell lung Cancer. J Nucl Med. 2017;58:569–76. https://doi.org/10.2967/jnumed.116.181826.CrossRefPubMedPubMedCentral

32.

Liao S, Penney BC, Zhang H, Suzuki K, Pu Y. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in stage IV nonsurgical small-cell lung cancer. Acad Radiol. 2012;19:69–77. https://doi.org/10.1016/j.acra.2011.08.020.CrossRefPubMed

33.

Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012;264:559–66. https://doi.org/10.1148/radiol.12111148.CrossRefPubMed

34.

Im HJ, Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, et al. Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis. Eur J Nucl Med Mol Imaging. 2015;42:241–51. https://doi.org/10.1007/s00259-014-2903-7.CrossRefPubMed

35.

Lee JK, Park HS, Kim DW, Kulig K, Kim TM, Lee SH, et al. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. Cancer. 2012;118:3579–86. https://doi.org/10.1002/cncr.26668.CrossRefPubMed

36.

Yang P, Kulig K, Boland JM, Erickson-Johnson MR, Oliveira AM, Wampfler J, et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol. 2012;7:90–7. https://doi.org/10.1097/JTO.0b013e31823c5c32.CrossRefPubMedPubMedCentral

37.

Blackhall FH, Peters S, Bubendorf L, Dafni U, Kerr KM, Hager H, et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European thoracic oncology platform Lungscape project. J Clin Oncol. 2014;32:2780–7. https://doi.org/10.1200/jco.2013.54.5921.CrossRefPubMed

38.

Kim TJ, Lee CT, Jheon SH, Park JS, Chung JH. Radiologic characteristics of surgically resected non-small cell lung Cancer with ALK rearrangement or EGFR mutations. Ann Thorac Surg. 2016;101:473–80. https://doi.org/10.1016/j.athoracsur.2015.07.062.CrossRefPubMed

39.

Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH, Tsai MF, et al. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol. 2012;7:98–104. https://doi.org/10.1097/JTO.0b013e3182370e30.CrossRefPubMed

40.

Jin Y, Sun PL, Park SY, Kim H, Park E, Kim G, et al. Frequent aerogenous spread with decreased E-cadherin expression of ROS1-rearranged lung cancer predicts poor disease-free survival. Lung Cancer (Amsterdam, Netherlands). 2015;89:343–9. https://doi.org/10.1016/j.lungcan.2015.06.012.CrossRef

41.

Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247–53. https://doi.org/10.1200/jco.2009.22.6993.CrossRefPubMedPubMedCentral

42.

Solomon B. Validating ROS1 rearrangements as a therapeutic target in non-small-cell lung cancer. J Clin Oncol. 2015;33:972–4. https://doi.org/10.1200/jco.2014.59.8334.CrossRefPubMed

43.

Zhang Q, Wu C, Ding W, Zhang Z, Qiu X, Mu D, et al. Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer. Thorac Cancer. 2019;10:47–53. https://doi.org/10.1111/1759-7714.12899.CrossRefPubMed

44.

Koh Y, Kim DW, Kim TM, Lee SH, Jeon YK, Chung DH, et al. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. J Thorac Oncol. 2011;6:905–12. https://doi.org/10.1097/JTO.0b013e3182111461.CrossRefPubMed

45.

Paik JH, Choi CM, Kim H, Jang SJ, Choe G, Kim DK, et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer (Amsterdam, Netherlands). 2012;76:403–9. https://doi.org/10.1016/j.lungcan.2011.11.008.CrossRef

46.

Kim TJ, Park CK, Yeo CD, Park K, Rhee CK, Kim J, et al. Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage. J Surg Oncol. 2014;110:245–51. https://doi.org/10.1002/jso.23646.CrossRefPubMed

47.

Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol. 2003;24:209–18. https://doi.org/10.1159/000074432.CrossRefPubMed

48.

Wang L, Wang D, Zheng G, Yang Y, Du L, Dong Z, et al. Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer. Int J Biol Markers. 2016;31:e80–7. https://doi.org/10.5301/jbm.5000177.CrossRefPubMed

49.

Chen Y, Gao SG, Chen JM, Wang GP, Wang ZF, Zhou B, et al. Serum CA242, CA199, CA125, CEA, and TSGF are biomarkers for the efficacy and prognosis of Cryoablation in pancreatic Cancer patients. Cell Biochem Biophys. 2015;71:1287–91. https://doi.org/10.1007/s12013-014-0345-2.CrossRefPubMed

50.

Zhong W, Yu Z, Zhan J, Yu T, Lin Y, Xia ZS, et al. Association of serum levels of CEA, CA199, CA125, CYFRA21-1 and CA72-4 and disease characteristics in colorectal cancer. Pathol Oncol Res. 2015;21:83–95. https://doi.org/10.1007/s12253-014-9791-9.CrossRefPubMed

51.

Sheu CC, Chang MY, Chang HC, Tsai JR, Lin SR, Chang SJ, et al. Combined detection of CEA, CK-19 and c-met mRNAs in peripheral blood: a highly sensitive panel for potential molecular diagnosis of non-small cell lung cancer. Oncology. 2006;70:203–11. https://doi.org/10.1159/000094321.CrossRefPubMed

52.

Foa P, Fornier M, Miceli R, Seregni E, Santambrogio L, Nosotti M, et al. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res. 1999;19:3613–8.PubMed

53.

Wang WT, Li Y, Ma J, Chen XB, Qin JJ. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients. Asian Pac J Cancer Prev. 2014;15:3927–32.CrossRef

54.

Ishiguro F, Fukui T, Mori S, Katayama T, Sakakura N, Hatooka S, et al. Serum carcinoembryonic antigen level as a surrogate marker for the evaluation of tumor response to chemotherapy in nonsmall cell lung cancer. Ann Thorac Cardiovasc Surg. 2010;16:242–7.PubMed

55.

Horinouchi H, Sekine I, Sumi M, Ito Y, Nokihara H, Yamamoto N, et al. Brain metastases after definitive concurrent chemoradiotherapy in patients with stage III lung adenocarcinoma: carcinoembryonic antigen as a potential predictive factor. Cancer Sci. 2012;103:756–9. https://doi.org/10.1111/j.1349-7006.2012.02217.x.CrossRefPubMed

56.

Wang Z, Yang S, Lu H. Preoperative serum carcinoembryonic antigen levels are associated with histologic subtype, EGFR mutations, and ALK fusion in patients with completely resected lung adenocarcinoma. Onco Targets Ther. 2017;10:3345–51. https://doi.org/10.2147/ott.s134452.CrossRefPubMedPubMedCentral

57.

Miao Y, Zhu S, Li H, Zou J, Zhu Q, Lv T, et al. Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naive advanced lung adenocarcinoma. J Thorac Dis. 2017;9:3927–37. https://doi.org/10.21037/jtd.2017.08.134.CrossRefPubMedPubMedCentral

58.

Fukui T, Yatabe Y, Kobayashi Y, Tomizawa K, Ito S, Hatooka S, et al. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer (Amsterdam, Netherlands). 2012;77:319–25. https://doi.org/10.1016/j.lungcan.2012.03.013.CrossRef

59.

Thunnissen E, Kerr KM, Herth FJ, Lantuejoul S, Papotti M, Rintoul RC, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer (Amsterdam, Netherlands). 2012;76:1–18. https://doi.org/10.1016/j.lungcan.2011.10.017.CrossRef

Title: Correlation between combining 18F–FDG PET/CT metabolic parameters and other clinical features and ALK or ROS1 fusion in patients with non-small-cell lung cancer
Authors: Maomei Ruan
Liu Liu
Lihua Wang
Bei Lei
Xiaoyan Sun
Cheng Chang
Yan Shen
Wenhui Xie
Publication date: 01-05-2020
Publisher: Springer Berlin Heidelberg
Keywords: Lymphoma
NSCLC
Lung Cancer
Lung Cancer
NSCLC
Lung Cancer
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04652-6

At a glance: The STEP trials

Springer Medicine

Correlation between combining ¹⁸F–FDG PET/CT metabolic parameters and other clinical features and ALK or ROS1 fusion in patients with non-small-cell lung cancer

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2020

Quantification of 18F-fluorodeoxyglucose uptake to detect residual nodal disease in locally advanced head and neck squamous cell carcinoma after chemoradiotherapy: results from the ECLYPS study

18F-FDG PET/CT in diagnostic and prognostic evaluation of patients with cardiac masses: a retrospective study

18F-FDG PET/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients

Imaging features of 2019 novel coronavirus pneumonia

Biological correlates of tumor perfusion and its heterogeneity in newly diagnosed breast cancer using dynamic first-pass 18F-FDG PET/CT

Tumour and pelvic lymph node metabolic activity on FDG-PET/CT to stratify patients for para-aortic surgical staging in locally advanced cervical cancer